Immunotech Biopharm Ltd (HKG:6978)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
2.350
-0.050 (-2.08%)
At close: Mar 6, 2026
Market Cap1.45B +9.3%
Revenue (ttm)n/a
Net Income-244.91M
EPS-0.48
Shares Out617.50M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume197,000
Average Volume222,907
Open2.430
Previous Close2.400
Day's Range2.350 - 2.450
52-Week Range2.340 - 5.830
Beta0.57
RSI35.84
Earnings DateMar 27, 2026

About Immunotech Biopharm

Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People’s Republic of China. The company’s core product is EAL, a multi-target cellular immunotherapy product that is in Phase III clinical trials for the prevention of postsurgical recurrence of liver cancer. It also develops 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer; CAR-T-19 injection product for B-cell acute ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 173
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 6978
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements